key: cord-0771708-5doyxgg8
authors: Mohanka, Manish R.; Joerns, John; Lawrence, Adrian; Bollineni, Srinivas; Kaza, Vaidehi; Cheruku, Sreekanth; Leveno, Matthew; Chen, Catherine; Terada, Lance S.; Kershaw, Corey D.; Torres, Fernando; Peltz, Matthias; Wait, Michael A.; Hackmann, Amy E.; Banga, Amit
title: ECMO Long Haulers: A Distinct Phenotype of COVID-19–Associated ARDS With Implications for Lung Transplant Candidacy
date: 2022-02-07
journal: Transplantation
DOI: 10.1097/tp.0000000000004052
sha: bc2c59d08ddd2807be6fb4fac146f108810c7e09
doc_id: 771708
cord_uid: 5doyxgg8

Studies indicate that the recovery from coronavirus disease 2019 (COVID-19)–associated acute respiratory distress syndrome may be slower than other viral pneumonia. There are limited data to guide decisions among patients who need extracorporeal membrane oxygenation (ECMO) support, especially the expected time of recovery and considering lung transplantation (LT). METHODS. This was a retrospective chart review of patients with COVID-19–associated acute respiratory distress syndrome placed on ECMO between March 1, 2020, and September 15, 2021 (n = 20; median age, 44 y; range, 22–62 y; male:female, 15:5). We contrasted the baseline variables and clinical course of patients with and without the need for ECMO support >30 d (ECMO long haulers, n = 10). RESULTS. Ten patients met the criteria for ECMO long haulers (median duration of ECMO, 86 d; range, 42–201 d). The long haulers were healthier at baseline with fewer comorbidities but had worse pulmonary compliance and higher partial pressure of CO(2). They had a significantly higher number of membrane oxygenator failures, changes to their cannulation sites, and suffer more complications on ECMO. One of the long hauler was bridged to LT while another 6 patients recovered and were discharged. Overall survival was better among the ECMO long haulers (70% versus 20%; 9.3, 1.2–73; P = 0.03). CONCLUSIONS. Despite worse pulmonary physiology, frequent complications, and a tortuous hospital course that may appear to portend a poor prognosis, ECMO long haulers have the potential to recover and be weaned off ECMO without the need for LT. A customized approach comprising a more conservative timeline for the consideration of LT may be prudent among these patients.

The emergence of coronavirus disease 2019 (COVID- 19) , caused by the novel severe acute respiratory syndrome coronavirus 2 has caused significant morbidity and mortality across the world. 1,2 Acute respiratory distress syndrome (ARDS) is the most common manifestation of COVID-19, resulting in intensive care unit (ICU) admission. In a large systemic review, extracorporeal membrane oxygenation (ECMO) support was needed among 6.4% of the patients with ARDS. 3 Although previous studies have demonstrated a survival benefit with ECMO for ARDS because of a variety of causes, 4 several unique characteristics converge in COVID-19-associated ARDS. A profound cytokine storm, 5 the activation of coagulation pathways in pulmonary circulation, 6 phenotypic diversity in pulmonary physiology, 7 and therapeutics that predispose to secondary infections 8, 9 are fairly unique to patients with severe COVID-19. Of importance, many of these characteristics cross-react with ECMO as a rescue strategy, which itself is associated with activation of inflammatory pathways, hematological dysfunction including bleeding and clotting, and increased susceptibility to systemic infections. 10, 11 There is preliminary evidence of how this may translate clinically, with COVID-19-associated ARDS increasing the risk of thrombotic ECMO circuit complications. 12 It has also been noted that recovery from COVID-19-associated ARDS may be slower than that from other viral pneumonia, 13 leading to recommendations that lung transplantation (LT) should not be considered for at least 4-6 wk from the onset of respiratory failure. 14 In a recent multinational report of 12 patients with severe COVID-19, LT was considered among patients with persistent ARDS for 4 wk or more. There appears to be an agreement in the transplant community regarding this timeline-long enough to alleviate the concerns for ongoing inflammation related to active viral replication while avoiding too much delay where patients become too debilitated or develop other complications that may render them poor transplant candidates. 15 Regardless, there are limited data to guide decisions regarding ECMO support, including appropriate expectations for time to recovery as a destination and the time to transition the goals of ECMO and consider LT.

In the current study, we report our experience of managing patients with severe ARDS from COVID-19 with refractory hypoxemia necessitating ECMO support. Specifically, we focused on patients requiring ECMO support >30 d. Among these patients, LT was considered as a destination therapy because of their lack of clinical progress. We refer to this cohort as the "ECMO long haulers" and describe their presentation, clinical course, and outcomes.

The current study was a single-center retrospective chart review study approved by the University of Texas Southwestern Institutional Review Board (# STU-2020-0489). All patients with COVID-19-associated ARDS placed on ECMO between March 1, 2020, and June 1, 2021, were included. The diagnosis of severe acute respiratory syndrome coronavirus 2 infection was based upon a positive polymerase chain reaction assay via nasopharyngeal swab sample.

All patients with COVID-19-associated ARDS were admitted to a dedicated ICU. The diagnosis of ARDS was based upon the Berlin definition. 16 The management of ARDS was at the discretion of the treating physician and followed the available recommendations at the time. 17 Patients were considered for venovenous (VV)-ECMO support as a bridge to recovery if they had refractory hypoxemia with or without hypercapnia despite maximal supportive care. A multidisciplinary team consisting of the intensivist, ECMO pulmonologist, and cardiothoracic surgeon reviewed each patient being considered for ECMO and reached a collaborative decision. Some of the patients (n = 4) were cannulated at a referring facility before transfer in consultation with the multidisciplinary team.

All patients underwent transthoracic echocardiogram before ECMO initiation to assess the appropriateness of VV-ECMO as the extracorporeal support strategy. The choice of ECMO cannula and access site was the prerogative of the cardiothoracic surgeon. All the procedures were done at the bedside to avoid transporting unstable patients to the operating room and minimize infection transmission risk. Patients were typically deisolated and transferred out of the COVID ICU per Centers for Disease Control and Prevention guidelines.

Once patients were on ECMO, efforts were made to wean mechanical ventilation in an effort to "rest" the lungs. Extubation was considered in all patients if the oxygenation and ventilatory needs were adequately met. Most patients were considered for tracheostomy if unable to extubate, and the ventilator settings could be weaned enough to allow the procedure. Attempts were made to wean sedation and analgesics to allow awakening the patients. Daily assessments were made by the physical and occupational therapy teams to maintain conditioning and rehabilitate the patients. Awake patients were encouraged to participate in physical therapy, including sitting up in bed, getting out in a chair, and walking with assistance. All patients were on some form of enteral nutritional support. Anxiety and delirium were anticipated and managed proactively in each patient with a multimodality strategy, including avoiding culprit medications as able, nonpharmacologic reorientation techniques, and pharmacotherapy when suitable. Psychiatry team was consulted in a majority of the patients to assist in the management. Family members were encouraged to spend time with the patients once they had been deisolated.

Although the initial goal for ECMO was a bridge to recovery among all patients, LT was considered among patients who remained ECMO dependent for >30 d (n = 10). Lack of pulmonary recovery compounded by the development of nonpulmonary organ dysfunction or recalcitrant infectious complications was ground for withdrawal of care and termination of ECMO support.

All patient variables were directly recorded from the electronic medical records. These consisted of demographics, comorbidities, presenting symptoms, the timing of diagnosis, disease progression necessitating intubation and ECMO support, and Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. 18 The details pertaining to ECMO such as access site, type of cannula, clinical course including ECMO, ventilator, and blood gas variables before and during the period of ECMO support, and complications during the hospital course were also recorded. The severity of the ARDS was assessed radiologically by the validated Radiographic Assessment of Lung Edema score 19 in a prospective manner. We focused on the subgroup of ECMO long haulers where LT was considered and reviewed the decision making among such patients.

Data were described using proportions and median with the range as appropriate. We contrasted the baseline variables and clinical course of patients with ECMO support >30 d to those with ≤30 d. We used the Mann-Whitney U test for continuous variables and the chi-square test for categorical variables. With death or need of LT as a composite endpoint, Kaplan-Meier curves were constructed to analyze the 2 groups. Analysis for outcome started at the time of diagnosis of COVID-19, and patients were censored at the time of death or at follow-up until September 15, 2021. Statistical significance was considered at P < 0.05 (2-tailed only).

During the study period, ECMO support was used for 20 patients for COVID-19-associated ARDS (Figure 1) . A majority were supported with VV-ECMO (n = 18), and femoral-femoral route was the most common access site (n = 17). Patients were on ECMO support for a median period of 36 d (range, 7-201 d), and 10 patients (50%) were successfully weaned from ECMO. Overall hospital survival was 42% (8/19), with 1 patient (bridged to LT off of ECMO) still in the hospital at the time of this report.

Among the study group, 10 patients met the criteria for ECMO long haulers (ECMO support for >30 d). The characteristics of patients with and without prolonged ECMO support are detailed in Table 1 . ECMO long haulers had similar demographics but a significantly lower number of comorbidities, and none of the patients in this cohort were immunocompromised. RESP score was similar for both the groups at the time of cannulation, although the long haulers had a significantly longer time between intubation and ECMO initiation. The trajectory of the ECMO-related variables was similar between the 2 groups ( Figure S1 , SDC, http://links.lww.com/ TP/C349). However, long haulers appeared to have worse ARDS physiologically, as indicated by lower pulmonary compliance and minute ventilation, as well as higher partial pressure of CO 2 (Figures S2 and S3 , SDC, http://links.lww. com/TP/C349) although radiologically, the 2 groups appeared similar ( Figure S4 , SDC, http://links.lww.com/TP/C349).

ECMO long haulers had a significantly higher number of oxygenator failures requiring a change of the ECMO circuit, although the number of days per oxygenator was significantly higher among the long haulers. They were more likely to need changes to their cannulation sites and appeared to suffer more complications, including a higher incidence of right ventricular (RV) dysfunction. Regardless, the outcomes were better among the ECMO long haulers with higher survival (P = 0.03) and lower incidence of the composite endpoint of need for LT or death (P = 0.07). Kaplan-Meier survival curves with the composite endpoint of need for LT or death for the two groups is presented in Figure 2 (log rank comparison P = 0.008).

The cohort consisted predominantly of young males. The majority of patients were <50 y (70%). None of the patients had significant comorbid illnesses involving other organ systems with obesity (body mass index >30 kg/m 2 ) being the most comorbidity (60%). Apart from antihypertensives (n = 3), none of the patients were on any long-term medications before getting COVID-19.

The median RESP score for the group was -0.5 (range, -4 to 3), with a majority of the patients in risk class III with an expected hospital survival of 57%. All patients had severe ARDS with partial pressure of O 2 :fraction of inspired O 2 (FiO 2 ) ratio <100, whereas concomitant hypercapnia was present among 8 patients. Except for 1 patient (#8) who was cannulated while still on high flow oxygen, all patients were intubated and supported on mechanical ventilation. All 9 ventilated patients had refractory hypoxemia despite prone positioning, neuromuscular blockade, and inhaled nitric oxide. All patients progressed despite receiving the available COVID-19-directed therapies, including remdesivir and dexamethasone. The median time from the diagnosis of COVID-19 to intubation was 11 d (5-18 d), whereas patients were initiated on ECMO after 8 d (1-35 d) from intubation. Patient #8 was cannulated while on high flow oxygen 11 d after the diagnosis of COVID-19 but needed intubation on day 77 of ECMO support. Figure S5 (SDC, http://links. lww.com/TP/C349) shows the timeline regarding the clinical course of each of the 10 patients in the study group.

All patients developed significant complications during their clinical course. Nearly all patients needed at least 2 or more oxygenator changes because of deterioration in the oxygenation capacity due to fibrin and thrombus buildup. A majority of the patients (n = 7) needed modifications in their cannulation strategies (Figure S6 , SDC, http://links. lww.com/TP/C349). The decision to change cannulation strategy was driven either by the need to support the RV via transition to an oxy-RV assist device (RVAD) cannula or permit mobilization to maintain physical function. The type and duration of various cannulation strategies used in each patient are presented in Figure S6 (SDC, http://links. lww.com/TP/C349). A significant proportion of patients developed RV dysfunction signified by the presence of moderate or worse RV dilation and systolic dysfunction (n = 8, 80%) on transthoracic echocardiogram, and 6 of these patients developed signs of RV failure that necessitated transition to oxy-RVAD.

Pleural complications developed among 7 patients (70%). Six patients developed pneumothorax that was managed with tube thoracostomy, and 4 of these patients required multiple chest tubes. Three patients developed massive hemothorax requiring multiple blood transfusions. Two of these patients required surgical thoracotomy.

Given the prolonged ECMO course and lack of pulmonary recovery, LT was considered among all the long haulers and majority were initiated on formal transplant evaluation (8/10). Two patients (#1 and #5 on Figures S5  and S6 , SDC, http://links.lww.com/TP/C349) were felt to be recovering at the time of referral or after transplant evaluation and deferred (decannulated on ECMO day 42 and 47, respectively). Another patient who was morbidly obese and developed dialysis-dependent acute renal failure was also denied for LT (patient #9, died on ECMO day 94 from RV failure). This patient was unsuitable for oxy-RVAD because of the need for high ECMO flows. Three patients (#4, #6, and #7) were deemed unsuitable for LT because of lack of adequate social support, and 1 patient (#3) was found to have an acute cerebellar hemorrhage that precluded further consideration for LT. One of the 3 patients with social barriers died after a prolonged hospital course (patient #7, ECMO day 117, see Figure S7 , SDC, http://links.lww.com/TP/C349) because of septic shock and acute renal failure, whereas the other 3 patients recovered and were decannulated.

The remaining 3 patients were approved and waitlisted for LT. One patient underwent bilateral LT after 138 d of ECMO support and was decannulated soon afterward (patient #10 on Figures S5 and S6 , SDC, http://links.lww.com/TP/C349). However, the other 2 patients did not get transplanted. One patient (#2) was active on the transplant waitlist for 31 d but had few suitable offers because of immune sensitization and lung sizing issues. The patient was inactivated as they started to show signs of pulmonary recovery and was eventually decannulated on ECMO day 87 (see Figure 3 ). The other patient (#8) was waitlisted for 47 d and also had limited donor offers (rare blood type and lung sizing issues). Unfortunately, the patient developed several complications during their hospital course-acute renal failure requiring dialysis support, enterococcus bacteremia, and candidemiaand was ultimately delisted. The patient was eventually transitioned to comfort care on ECMO day 201 as debility was high, and there was no sign of pulmonary recovery.

The trajectory of ECMO, ventilator, and blood gas parameters were compared among long haulers who survived without needing an LT (n = 6) versus those who died or needed an LT (n = 4). These data are presented in Figures 4-6 .

A majority of the long haulers recovered enough pulmonary function to enable weaning from the ECMO (6/10, 60%) and were eventually discharged from the hospital. The median duration of ECMO support among the long haulers was 86 d (range, 42-201 d) for the overall group and 61 d among the eventual survivors (n = 6). The survivors spent an additional 21 d (17-73 d) in the hospital after ECMO decannulation. Two patients recovered enough to be directly discharged home, whereas the remaining 4 patients were discharged to another facility (long-term acute care hospital [n = 3] and acute rehabilitation unit [n = 1]) before returning home. Follow-up data were available for a median period of 6 mo (range, 5-10 mo) since the COVID-19 diagnosis for all the long-haul survivors. Spirometry was available among 4 patients, and all showed a restrictive ventilatory defect (median predicted forced vital capacity, 44.5%; range, 39%-50%). Two patients remained oxygen dependent with 1 patient slowly being weaned down at the time of this report. The other patient did not show any significant improvement in their pulmonary status and met the criteria of advanced lung disease. Given the lack of improvement >8 mo after COVID-19, this patient was evaluated and approved for LT. He was eventually transplanted >10 mo from COVID-19 and >6 mo after decannulation.

The current study describes a series of patients with severe ARDS from COVID-19 who needed prolonged ECMO support with acceptable hospital survival. It has been our clinical observation that COVID-19 patients needing ECMO support require longer times to recover than those with ARDS from other causes. We have witnessed our longest ECMO runs during the COVID-19 pandemic since establishing our ECMO program in 2013. Although definitive data are lacking, early reports also suggest longer recovery times among patients with ARDS from COVID-19.

The analysis comparing the 2 groups based on the duration of ECMO support highlights the profound impact of chronic conditions and comorbidities on outcomes among these patients. Long haulers seemed to have physiologically worse ARDS than the other group and developed more complications during the hospital course but experienced better outcomes. The long-hauler phenotype seems to be typified by otherwise healthy patients without significant comorbidities who can survive long enough to allow pulmonary recovery. On the other hand, the non-long haulers may have less severe pulmonary impairment physiologically but have the baggage of significant comorbidities, which appears to be the key determinant impacting outcomes. A small minority of patients in the non-long-hauler group tend to recover in the usual time frame of 2-3 wk (perhaps related to the "milder ARDS"), but the majority succumb to complications on ECMO. Notably, 7 of 8 nonsurvivors in the nonlong-hauler group had significant comorbidities (2 with a history of organ transplant, 2 with ESRD, 2 with morbid obesity with body mass index >40, and 1 with pulmonary sarcoidosis). The earliest reports of ECMO use among COVID-19 patients from China 20 reported high mortality, and there was little concern about potential issues related to prolonged ECMO support. Subsequently, reports from the United States validated the role of ECMO for severe ARDS, although there was incomplete hospital followup among several patients. 21, 22 In fact, more than half the patients (17/32) in one of these reports were still on ECMO after 3 wk of cannulation, indicating a prolonged clinical course. 21 This is significantly longer than the average ECMO support of <2 wk with other viral pneumonia in the Extracorporeal Life Support Organization registry database. 23 The past experience at our institution has also been similar with much shorter ECMO runs for other indications. 10,24 FIGURE 6. Trends in the arterial blood gas variables, namely pH, Paco 2 , and Pao 2 to FiO 2 ratio among long haulers who survived without needing a lung transplant (n = 6) vs those who died or needed a lung transplant (n = 4). *P < 0.05. FiO 2 , fraction of inspired O 2 ; LT, lung transplantation; PaCO 2 , partial pressure of CO 2 ; PaO 2 , partial pressure of O 2 .

There is increasing evidence linking COVID-19 with prolonged ECMO runs. A recent German study 25 reported that most of their ECMO survivors (7/11, 63.6%) needed support ≥28 d, similar to our findings where three-fourth of the survivors needed >30 d of ECMO support (Figure 1 ). In a larger multicenter study of ECMO patients with COVID-19 from France, 26 there was a 35% probability of these patients remaining on ECMO support by ICU day 28. Furthermore, the median duration of ECMO support in this study was nearly double that of patients in the ECMO to Rescue Lung Injury in Severe ARDS trial. 4 The data on survival among COVID-19 patients needing ECMO have been mixed. As compared to those with influenza, early studies among COVID-19 patients, although smaller in size, reported worse survival. 20, 27 However, more recent and larger studies have reported findings to the contrary. Although some of these studies were limited by incomplete follow-up among a significant proportion of patients, the early survival is estimated to be equivalent to patients supported on ECMO for other indications. 4, 26, 28, 29 It appears that despite the significantly longer stay on ECMO, patients with COVID-19 do not experience worse survival.

Although the utilization of ECMO as a bridge to LT is expected to increase among COVID-19 patients as the strain on the healthcare systems lessens, only a handful of patients globally have reportedly undergone LT following ARDS from COVID-19. 15, 30 Despite encouraging early outcomes for LT as salvage therapy, it is pertinent to gather more experience with larger study groups and longer follow-up. With the benefit of hindsight, the decision to defer LT for 2 patients in our cohort who seemed to have subtle signs of improvement in their pulmonary compliance (despite persistently high FiO 2 needs and with both being >6 wk since the onset of respiratory failure) was appropriate as they both eventually recovered and were discharged home. Despite a long and complicated stay, 4 additional patients survived to hospital discharge, and their clinical course should be instructive in assessing future patients for LT candidacy. The course of one of the waitlisted patients (patient #2 on Figure S5 and S6, SDC, http://links.lww. com/TP/C349) deserves special mention. The decision to waitlist the patient seemed appropriate as there was persistent ECMO dependence, and pulmonary parenchyma appeared to have significant fibrotic changes ( Figure 3 ). However, the patient started to show improvement in pulmonary physiology after several weeks of ECMO support, and the parenchymal opacities, despite lagging behind early on, also began to improve. It is indeed possible that some of the long haulers weaned from ECMO will need LT in the future, as noted with patient #3. However, posttransplant outcomes are likely better if patients recover from their acute illness, liberate from ECMO, and rehabilitate mentally and physically before pursuing LT. Of course, this approach needs to be balanced against the risk of waiting too long where patients develop complications on ECMO or get too debilitated or frail to remain transplant candidates.

Given the current dynamics of the pandemic, the LT professionals are likely to be increasingly involved in the care of ECMO long haulers and asked to opine regarding the transplant candidacy of these patients. Typically, recovery from severe viral pneumonia leading to ARDS, with influenza as the prototype, is anticipated in 4-6 wk, and patients with continued need of ECMO support would be considered for LT. 14, 15 In this regard, it is important to appreciate that the clinical course of COVID-19-associated ARDS appears to be distinctly different from other viral pneumonia. The concern regarding the potential for improvement and recovery from ARDS in any patient being considered for LT may be more accentuated among patients with COVID-19, which is a novel disease not seen during the "bridging era" of LT. A longer recovery period with equivalent hospital survival among these patients dictates reconsideration of the 4-to 6-wk timeline, as demonstrated in our patient series. The trajectory of ECMO and ventilator variables among the long haulers (Figures 4 and 5) provides an insight into the time it may take for pulmonary recovery among these patients. The curves appear to start separating between 4 and 6 wk, and the improvement seems to extend well into the third month of ECMO.

Although there is a pressing need for additional data on outcomes among these patients, it may be appropriate to follow a more conservative timeline in considering LT as the ECMO destination among patients with COVID-19. While pursuing such a strategy, we propose that some common complications should be preempted and managed proactively. Pleural complications are exceedingly common and tend to be recalcitrant. Pneumothorax was frequent, and we found the use of image-guided smallerbore chest tubes safer among these patients as they were less likely to be complicated by hemothorax. In situations where hemothorax did develop, surgical intervention with washout may be needed to allow the underlying lung to expand. Another common challenge among patients on prolonged ECMO support is the development of progressive RV dilation and dysfunction. We found the transition to oxy-RVAD cannulation to help decompress the RV and prevent further worsening.

Although it would be helpful to identify objective parameters that could dictate decision making in such situations, it is unlikely that any simple tool would predict outcomes accurately among patients with a dynamic and complex clinical course. The standard of care in such situations remains the time-tested multidisciplinary and collaborative approach followed by most LT teams. Beyond that, we propose that the assessments for the timing of LT candidacy occur on a longitudinal basis instead of a cross-sectional manner to enable the best decisions. Given the limited experience, although no strict timeline can be accurately recommended, it may be prudent to wait longer than one would for patients on ECMO because of other causes. Even in the presence of significant parenchymal opacities and profound physiological abnormalities, the potential for significant enough recovery to allow weaning from ECMO cannot be excluded among these patients. In uncertain situations, it may indeed be reasonable to initiate transplant evaluation and consider activation of the patients on the transplant waitlist. However, patients should be continually assessed for signs of pulmonary recovery, which may enable weaning from ECMO.

In summary, we report a series of COVID-19 patients needing prolonged ECMO support, referred to as ECMO long haulers. A significant proportion of patients with severe COVID-19, often those who are relatively healthier at baseline with fewer comorbid illnesses, may become ECMO long haulers. Despite a higher number of complications and a tortuous hospital course that may appear to portend a poor prognosis, these patients have the potential to recover and be weaned off ECMO. A customized approach comprising a more conservative timeline for the consideration of LT may be prudent among these patients.

An interactive web-based dashboard to track COVID-19 in real time

Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis

Global impact of coronavirus disease 2019 infection requiring admission to the ICU: a systematic review and meta-analysis

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Cytokine storm

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Management of COVID-19 respiratory distress

The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan)

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Effects of extracorporeal membrane oxygenation initiation on oxygenation and pulmonary opacities

COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review

Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19

The prolonged use of VV ECMO support in COVID-19: a case report

When to consider lung transplantation for COVID-19

Lung transplantation for severe post-coronavirus disease 2019 respiratory failure

ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition

19 Treatment Guidelines. Oxygen and ventilation

Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score

Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in coronavirus disease 2019: experience with 32 patients

The role of extracorporeal life support for patients with COVID-19: preliminary results from a statewide experience

Extracorporeal Life Support Organization registry international report 2016

Predictors of outcome among patients on extracorporeal membrane oxygenation as a bridge to lung transplantation

ECMO in COVID-19-prolonged therapy needed? A retrospective analysis of outcome and prognostic factors

Groupe de Recherche Clinique en REanimation et Soins intensifs du Patient en Insuffisance Respiratoire aiguE (GRC-RESPIRE) Sorbonne Université; Paris-Sorbonne ECMO-COVID Investigators. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Comparative outcomes between COVID-19 and influenza patients placed on veno-venous extracorporeal membrane oxygenation for severe ARDS

Analysis of COVID-19 patients with acute respiratory distress syndrome managed with extracorporeal membrane oxygenation at US academic centers

Extracorporeal Life Support Organization. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries